Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Sells $556,016.00 in Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver sold 49,600 shares of the firm’s stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $11.21, for a total value of $556,016.00. Following the completion of the transaction, the director now owns 210,346 shares of the company’s stock, valued at approximately $2,357,978.66. This represents a 19.08 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Laura Shawver also recently made the following trade(s):

• On Monday, February 3rd, Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $12.31, for a total value of $615,500.00.
• On Monday, January 6th, Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $11.10, for a total value of $555,000.00.

ARS Pharmaceuticals Trading Up 0.6 %

Shares of NASDAQ SPRY opened at $10.85 on Monday. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -21.27 and a beta of 1.03. ARS Pharmaceuticals, Inc. has a 1-year low of $7.55 and a 1-year high of $18.51. The stock’s 50-day moving average is $11.87 and its 200 day moving average is $13.12.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on SPRY. William Blair reaffirmed an “outperform” rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Oppenheimer began coverage on ARS Pharmaceuticals in a report on Monday, February 10th. They issued an “outperform” rating and a $40.00 price target on the stock. Raymond James raised their price target on ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a report on Tuesday, January 14th. Scotiabank began coverage on ARS Pharmaceuticals in a report on Friday. They issued a “sector outperform” rating and a $30.00 price target on the stock. Finally, Leerink Partners raised their price target on ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Monday, January 13th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $29.00.

Hedge Funds Weigh In On ARS Pharmaceuticals

Large investors have recently modified their holdings of the company. Bernard Wealth Management Corp. purchased a new position in ARS Pharmaceuticals in the 4th quarter worth approximately $27,000. KLP Kapitalforvaltning AS purchased a new position in ARS Pharmaceuticals in the 4th quarter worth approximately $73,000. BNP Paribas Financial Markets purchased a new position in ARS Pharmaceuticals in the 4th quarter worth approximately $75,000. Ball & Co Wealth Management Inc. purchased a new position in ARS Pharmaceuticals in the 4th quarter worth approximately $105,000. Finally, Compass Capital Corp MA ADV purchased a new position in ARS Pharmaceuticals in the 4th quarter worth approximately $106,000. 68.16% of the stock is owned by hedge funds and other institutional investors.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.